Rapid Dose Therapeutics Corp. (RDTCF)

Rapid Dose Therapeutics Income Statement

Financials in millions CAD. Fiscal year is March - February.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Feb 28, 2025	Feb 29, 2024	Feb 28, 2023	Feb 28, 2022	Feb 28, 2021
Revenue	2.09	1.02	0.72	1.75	0.76
Revenue Growth (YoY)	104.34%	42.06%	-59.00%	131.98%	644.05%
Cost of Revenue	0.91	0.46	0.36	0.41	0.13
Gross Profit	1.18	0.56	0.36	1.34	0.63
Selling, General & Admin	3.55	2.45	2.46	2.99	1.5
Research & Development	0.15	0.43	0.09	0.36	0.09
Operating Expenses	5.35	3.65	3.9	5.65	2.26
Operating Income	-4.17	-3.09	-3.54	-4.3	-1.63
Interest Expense	-1.23	-0.66	-0.26	-0.13	-0.14
Interest & Investment Income	-	-	-	0	-
Currency Exchange Gain (Loss)	-	-	-0	0.02	-0.03
Other Non Operating Income (Expenses)	-	-	-	0.01	-
EBT Excluding Unusual Items	-5.4	-3.75	-3.81	-4.4	-1.81
Impairment of Goodwill	-	-	-	-4.08	-
Other Unusual Items	-	-0.56	-	-	-
Pretax Income	-5.4	-4.31	-3.81	-8.49	-1.81
Net Income	-5.4	-4.31	-3.81	-8.49	-1.81
Net Income to Common	-5.4	-4.31	-3.81	-8.49	-1.81
Shares Outstanding (Basic)	125	105	103	100	78
Shares Outstanding (Diluted)	125	105	103	100	78
Shares Change (YoY)	18.68%	1.50%	3.19%	28.83%	2.23%
EPS (Basic)	-0.04	-0.04	-0.04	-0.08	-0.02
EPS (Diluted)	-0.04	-0.04	-0.04	-0.08	-0.02
Free Cash Flow	-1.15	-2.29	-0.86	-3.04	-1.63
Free Cash Flow Per Share	-0.01	-0.02	-0.01	-0.03	-0.02
Gross Margin	56.59%	55.21%	49.67%	76.76%	83.40%
Operating Margin	-200.07%	-302.45%	-493.36%	-245.55%	-216.45%
Profit Margin	-259.18%	-422.03%	-530.42%	-484.47%	-239.04%
Free Cash Flow Margin	-55.27%	-224.91%	-120.27%	-173.52%	-216.20%
EBITDA	-3.95	-2.75	-3.2	-3.82	-1.25
EBITDA Margin	-189.66%	-269.93%	-	-218.31%	-165.21%
D&A For EBITDA	0.22	0.33	0.34	0.48	0.39
EBIT	-4.17	-3.09	-3.54	-4.3	-1.63
EBIT Margin	-200.07%	-	-	-245.55%	-216.45%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.